摘要
目的探讨替米沙坦治疗糖尿病早期肾病的临床疗效及肾脏保护作用。方法 62例2型糖尿病早期肾病患者,随机分为对照组和治疗组,治疗组加用替米沙坦40mg/d,对照组加用相同剂量的安慰剂。对所有纳入对象测定治疗前后糖化血红蛋白（HbA1c）、血脂、血清钾浓度（cK＋）、24h尿白蛋白排泄率（UAER）,内生肌酐清除率（Ccr）。结果治疗组患者UAER水平明显下降（P〈0.05）。结论替米沙坦能延缓糖尿病肾病（DN）的发生和发展,建议糖尿病早期肾病患者常规应用。
Objective To explore the clinical effect and the protective effects of Telmisartan on early diabetic nephropathy（DN）.Methods A total of sixty-two patients were enrolled in the randomized controlled study.They were randomly divided into observation group and control group.The observation group received Telmisartan 40 milligram once daily while the control group received the same dosage of placebo.Before treatment,hemoglobin A1c、lipid、serum potassium、urinary albumin excretion rate（UAER） and creatinine clearance rate（Ccr） were assessed at the same time.All variables were measured in all subjects after treatment.Results There was significant difference of UAER leval before and after treatment（P0.05）.Conclusion Telmisartan has the protective effects on kidney and delays the advance of DN,It is recommended that Telmisartan may be conventionally used in the early stage of DN.
出处
《中外医疗》
2010年第23期36-36,38,共2页
China & Foreign Medical Treatment
关键词
替米沙坦
糖尿病肾病
治疗
Telmisartan
Diabetic nephropathy
Treatment
